Perifosine is an oral Akt inhibitor, currently evaluated in phase III clinical trials, shown to inhibit Akt and mitogen-activated protein kinase (MAPK) phosphorylation in prostate PC3 cells, multiple myeloma, HCC, glioma cells and renal carcinoma [50-54]. Here, WNK2 is linked to plasma cell myeloma.